Wolfe Research raised the price target for the Shockwave Medical Inc. (NASDAQ:SWAV) stock from “an Outperform” to “a Peer perform”. The rating was released on April 05, 2024, according to finviz. The research report from UBS has initiated the stock to Neutral, with a price target set at $218. The stock was upgraded by Morgan Stanley, who disclosed in a research note on July 10, 2023, from Equal-Weight to Overweight and set the price objective to $335. In their research brief published May 30, 2023, Morgan Stanley analysts resumed the Shockwave Medical Inc. stock to Equal-Weight with a price target of $291.
The latest trade, Performances and Moving Averages give us the following Picture
The firm’s stock price fluctuated -0.65% within the last five trades and 18.18% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 60.74% in the last 6 months and 49.72% was added to its value over the previous 3 months. SWAV stock is trading at a margin of 4.25%, 17.82% and 42.49% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of the close of trading, SWAV deals in the Healthcare domain. The stock is trading -1.23 percent below its 52-week high and 108.60 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 46.86. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Shockwave Medical Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at 22.42 percent and the profit margin is 20.17 percent, and the company has reported a gross margin of 86.94 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $12.25 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio for Shockwave Medical Inc. (NASDAQ:SWAV) is 84.82. The price-to-earnings ratio is a method of assessing corporate values by comparing them to their per-share profit. Forward P/E stands at 52.99. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 16.77 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 18.12, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 2.07 percent of Shockwave Medical Inc. shares are owned by insiders, and 95.15 percent are held by financial institutions. Zacharias Isaac, the President, CCO at Shockwave Medical Inc. (SWAV) has sold 4,000 shares of firm on Mar 26 ’24 at a price of $287.67 against the total amount of $1.15 million. In another inside trade, FRANCIS LAURA, Director of Shockwave Medical Inc. (NASDAQ:SWAV) sold 1,500 shares of the firm on Mar 26 ’24 for a total worth of $0.45 million at a price of $300.00. An inside trade which took place on Mar 06 ’24, Director of Shockwave Medical Inc. WATKINS FRANK T sold 2,000 shares of firm against total price of $0.51 million at the cost of $253.65 per share.
